Pharmacological Targeting of the CCL2/CCR2 Axis for Atheroprotection: A Meta-Analysis of Preclinical Studies.
Luka ŽivkovićYaw AsareJürgen BernhagenMartin DichgansMarios K GeorgakisPublished in: Arteriosclerosis, thrombosis, and vascular biology (2022)
Preclinical evidence suggests that pharmacological targeting of CCL2 or CCR2 might lower atherosclerotic lesion burden, but the majority of existing studies suffer major quality issues that highlight the need for additional high-quality research.